2019-nCoV drug discovery: HHS funds Regeneron mAbs and BenevolentAI deploys machine learning

Regeneron and BenevolentAI unveiled a deal and a platform, respectively, on Tuesday that could yield therapies against 2019-nCoV that go beyond anti-inflammatory drugs for other viral infections.

The first nine clinical trials of medicines for 2019-nCoV acute respiratory disease are evaluating approved HIV, HCV, flu or HBV drugs and anti-inflammatory steroids (see “Clinical Trials for Coronavirus”)...